Research Nester published a report titled “Polycystic Kidney Disease Drugs Market: Global Demand Analysis & Opportunity Outlook 2033” which delivers detailed overview of the global polycystic kidney disease drugs market  in terms of market segmentation by type, treatment, diagnosis, end user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global polycystic kidney disease drugs market is anticipated to grow with a CAGR of ~7% during the forecast period, i.e., 2023-2033. The market is segmented by type into autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and others. Out of these, the autosomal dominant polycystic kidney disease segment is anticipated to garner the largest revenue by the end of 2033.

 A growing number of autosomal dominant polycystic kidney diseases are being diagnosed worldwide, which is expected to drive segment growth during the forecast period.  It was observed that ADPKD prevalence in the general population is estimated at 1 in 500-1,000. 

The global polycystic kidney disease drugs market is estimated to garner revenue of USD 732 Million by the end of 2033, up from revenue of USD 451 Million in the year 2021. Rise in cases of chronic kidney and end stage renal diseases such as kidney failure, polycystic kidney disease, and increase in disposable income, improved healthcare infrastructure along with government initiatives to raise awareness about kidney diseases are some of the major factors anticipated to drive the growth of the market during the forecast period.

Geographically, the global polycystic kidney disease drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in North America is projected to garner the largest revenue by the end of 2033. 

The rise in per capita income in the region, increasing awareness of chronic kidney diseases, a comprehensive health care system, intensive pharmaceutical research and development, a significant growth in the healthcare and medical industries, and the accessibility of drugs are expected to drive regional market during the forecast period. 

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Increase in the Incidence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Drive the Market Growth

ADPKD affects about 200,000 to 500,000 Americans and another 13,000,000 people worldwide and about 25% of the population is unaware of the disease. 

Despite being a rare condition, ADPKD greatly contributes to chronic kidney disease and kidney failure. The prevalence of chronic kidney disease is substantially increased by polycystic kidney disease, the most common chronic kidney disease. Therefore, the global polycystic kidney disease drugs market is expected to grow owing to the increasing prevalence of ADPKD over the forecast period.

However, costly treatment is expected to operate as key restraint to the growth of the market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global polycystic kidney disease drugs market which includes company profiling of Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., Celgene Corp, XORTX Pharma Corp., ManRos Therapeutics, Palladio Biosciences, Regulus Therapeutics, Inc., Kadmon Holdings, Inc., Reata Pharmaceuticals, Inc., Pano Therapeutics,Inc.

The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global polycystic kidney disease drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.